EU Biosimilars: Video Analysis.
Watch our analysts discuss the latest EU developments and assess the prospects of leading players
By Giles Somers, Lead Analyst
16 October 2012
I head up the Generics and Biosimilars team at Datamonitor Healthcare, where we aim to provide clients with concise stra...
Read full bio
View a presentation of key findings from our extended database of 88 marketed and development stage EU biosimilars…
Biosimilars are more established in the EU than the US and Japan, with a total of 13 ‘first wave’ product approvals, but the prospects for complex products such as monoclonal antibodies remain unclear. A key event will be the review of Celltrion/Hospira’s version of Remicade (infliximab) – submitted to the EMA in April 2014. Its chances of success have improved following approval in Korea as Remsima on July 2012.
Assess the major opportunities and threats for the development pipelines of leading biosimilar companies in our exclusive video overview.